The Global Health Body Sounds Warning Over Critical Scarcity of Weight-Loss Medications
Fewer than a tenth of people that would benefit from obesity jabs including Wegovy have access to them, warns the global health agency as it releases its initial advice on the medications.
With more than one billion people worldwide currently living with obesity, it is urging more widespread and fairer availability to this class of drugs.
Based on forecasts, over two billion could be living with obesity by 2030 without intervention.
"The new guidelines affirms that obesity is a lifelong illness that can be treated with comprehensive and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and distribution challenges are key hurdles to broad access to the injections that can help people shift considerable body mass, notes the agency.
GLP-1 Therapy Supply Crisis
Even in the present most favorable scenario, the production of these medications could only cover around 100 million people – fewer than 10% of the global need, per the health organization.
The guideline calls on countries and companies to expand availability, by strategies including patent sharing.
The intellectual property rights on semaglutide – the main component of the drug Wegovy – is due to expire in several countries in 2026.
How Obesity Injections Operate
GLP-1 drugs replicate a body's own hormone to delay gastric emptying, curb appetite and enhance the sense of being full so people eat less.
Individuals typically begin shedding pounds in the initial weeks of commencing the regular doses.
Evidence indicates users may regain a significant portion after a year of halting the medication, because their usual hunger come back.
Being overweight or obese raises your risk for contracting health problems, like diabetes, heart disease, brain attack, and some malignancies.
Obesity concerns individuals in all nations and was responsible for over three and a half million deaths worldwide in 2024, per the health agency.
